"10.1371_journal.pone.0042017","plos one","2012-10-24T00:00:00Z","Nicolas Froger; Lucia Cadetti; Henri Lorach; Joao Martins; Alexis-Pierre Bemelmans; Elisabeth Dubus; Julie Degardin; Dorothée Pain; Valérie Forster; Laurent Chicaud; Ivana Ivkovic; Manuel Simonutti; Stéphane Fouquet; Firas Jammoul; Thierry Léveillard; Ryad Benosman; José-Alain Sahel; Serge Picaud","Institut National de la Santé et de la Recherche Médicale UMR 968, Institut de la Vision, Paris, France; Luniversité Pierre et Marie Curie, Université Paris 06, UMR_S 968, Institut de la Vision, Paris, France; Centre National de la Recherche Scientifique UMR7210, Institut de la Vision, Paris, France; Centre Hospitalier National dOphtalmologie des Quinze-Vingts, Paris, France; Institut des systèmes intelligents et robotique, luniversité Pierre et Marie Curie, Paris, France; Centre National de la Recherche Scientifique UMR7222, Paris, France; Institute of Ophthalmology, University College of London, London, United Kingdom; Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; French Academy of Sciences, Paris, France","Conceived and designed the experiments: NF L. Cadetti HL JM APB FJ TL RB JAS SP. Performed the experiments: NF L. Cadetti HL JM ED JD DP VF L. Chicaud MS II. Analyzed the data: NF L. Cadetti HL APB ED DP SF. Contributed reagents/materials/analysis tools: NF L. Cadetti APB MS SF FJ SP. Wrote the paper: NF L. Cadetti RB JAS SP.","JAS, TL, MS and SP were consultants at Fovea Pharma, which supported the study. A patent has been filed on the data, United States Patent Application 20120027723. The present invention relates to taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration. More particularly the invention relates to a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis for the prevention and treatment of a disease associated with retinal ganglion cell degeneration. There are no other patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.",NA,NA,NA,"2012","10","Nicolas Froger","NF",18,TRUE,2,2,2,2,TRUE,TRUE,TRUE,13,"4;5;6;7;8;9;11;12;13;14;16;17;18",TRUE
